Free Trial

Anebulo Pharmaceuticals (ANEB) Competitors

Anebulo Pharmaceuticals logo
$3.19 -0.05 (-1.54%)
Closing price 04:00 PM Eastern
Extended Trading
$3.20 +0.00 (+0.16%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANEB vs. MNPR, MREO, KOD, ZYBT, TVRD, INZY, AARD, ACB, NBTX, and PRQR

Should you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Monopar Therapeutics (MNPR), Mereo BioPharma Group (MREO), Kodiak Sciences (KOD), Zhengye Biotechnology (ZYBT), Tvardi Therapeutics (TVRD), Inozyme Pharma (INZY), Aardvark Therapeutics (AARD), Aurora Cannabis (ACB), Nanobiotix (NBTX), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry.

Anebulo Pharmaceuticals vs. Its Competitors

Monopar Therapeutics (NASDAQ:MNPR) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Monopar Therapeutics currently has a consensus price target of $60.00, indicating a potential upside of 33.42%. Anebulo Pharmaceuticals has a consensus price target of $5.50, indicating a potential upside of 72.41%. Given Anebulo Pharmaceuticals' higher probable upside, analysts plainly believe Anebulo Pharmaceuticals is more favorable than Monopar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monopar Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Anebulo Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Monopar Therapeutics' return on equity of -55.39% beat Anebulo Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Monopar TherapeuticsN/A -55.39% -51.53%
Anebulo Pharmaceuticals N/A -90.11%-84.53%

In the previous week, Anebulo Pharmaceuticals had 8 more articles in the media than Monopar Therapeutics. MarketBeat recorded 10 mentions for Anebulo Pharmaceuticals and 2 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 1.07 beat Anebulo Pharmaceuticals' score of 0.53 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monopar Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Anebulo Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monopar TherapeuticsN/AN/A-$15.59M-$3.48-12.92
Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-12.27

Monopar Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the S&P 500.

Summary

Anebulo Pharmaceuticals beats Monopar Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Anebulo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANEB vs. The Competition

MetricAnebulo PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$133.12M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-12.278.6721.1920.14
Price / SalesN/A328.69461.30104.37
Price / CashN/A42.7636.2258.56
Price / Book21.278.378.665.87
Net Income-$8.20M-$55.19M$3.25B$258.55M
7 Day Performance94.51%5.89%4.20%2.23%
1 Month Performance117.01%17.63%10.82%12.76%
1 Year Performance45.00%5.09%34.70%19.36%

Anebulo Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANEB
Anebulo Pharmaceuticals
2.0905 of 5 stars
$3.19
-1.5%
$5.50
+72.4%
+35.0%$133.12MN/A-12.274News Coverage
Analyst Forecast
MNPR
Monopar Therapeutics
2.2868 of 5 stars
$43.53
-0.5%
$60.00
+37.8%
+1,363.1%$267.35MN/A-12.5510Positive News
MREO
Mereo BioPharma Group
1.7907 of 5 stars
$1.66
-3.8%
$7.20
+335.0%
-55.9%$263.15M$10M-23.6440
KOD
Kodiak Sciences
2.5305 of 5 stars
$4.95
-4.4%
$9.00
+82.0%
+173.2%$261.22MN/A-1.3690
ZYBT
Zhengye Biotechnology
N/A$5.49
-6.5%
N/AN/A$258.94M$186.36M0.00278Positive News
Gap Up
TVRD
Tvardi Therapeutics
N/A$27.60
-7.5%
$64.25
+132.8%
N/A$258.34M$7.14M0.0080
INZY
Inozyme Pharma
2.7992 of 5 stars
$4.00
flat
$11.75
+193.8%
N/A$258.25MN/A-2.3750
AARD
Aardvark Therapeutics
N/A$11.64
-3.9%
$33.00
+183.5%
N/A$252.54MN/A0.0018
ACB
Aurora Cannabis
0.2778 of 5 stars
$4.48
-2.3%
N/A-16.5%$251.54M$246.72M40.681,130
NBTX
Nanobiotix
1.6198 of 5 stars
$5.33
+3.4%
$8.00
+50.2%
+22.0%$251.01M$39.18M0.00100News Coverage
Gap Up
PRQR
ProQR Therapeutics
2.8831 of 5 stars
$2.38
-4.2%
$8.00
+236.8%
+20.2%$249.87M$20.46M-6.79180

Related Companies and Tools


This page (NASDAQ:ANEB) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners